Treatment of Acute Pain in Patients on Naltrexone: A Narrative Review.
Acute pain
Multimodal pain control
Naltrexone
Opioids
Post-surgical pain
Journal
Current pain and headache reports
ISSN: 1534-3081
Titre abrégé: Curr Pain Headache Rep
Pays: United States
ID NLM: 100970666
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
accepted:
20
03
2023
medline:
2
6
2023
pubmed:
28
4
2023
entrez:
28
4
2023
Statut:
ppublish
Résumé
The tissue damage and trauma associated with surgery almost always result in acute postoperative pain. The intensity of postoperative pain can range from mild to severe. Naltrexone is suitable for patients who do not wish to be on an agonist treatment such as methadone or buprenorphine. However, naltrexone has been shown to complicate postoperative pain management. Multiple studies have found that the use of naltrexone can increase the opioid requirement for postoperative pain control. Other modalities exist that can help outside of opioids such as ketamine, lidocaine/bupivacaine, duloxetine, and non-pharmacological management can help manage pain. Multimodal pain regiments should also be employed in patients. In addition to traditional methods for postoperative pain management, other methods of acute pain control exist that can help mitigate opioid dependence and help control pain in patients who use naltrexone for their substance use disorders.
Identifiants
pubmed: 37115486
doi: 10.1007/s11916-023-01110-9
pii: 10.1007/s11916-023-01110-9
doi:
Substances chimiques
Naltrexone
5S6W795CQM
Buprenorphine
40D3SCR4GZ
Methadone
UC6VBE7V1Z
Analgesics, Opioid
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
183-192Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Loeser JD, Melzack R. Pain: an overview. Lancet. 1999.
Moore AR, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al. “Evidence” in chronic pain – establishing best practice in the reporting of systematic reviews. Pain. 2010;150(3):386–9.
pubmed: 20627575
McCarberg B, Gibofsky A. Need to develop new nonsteroidal anti-inflammatory drug formulations. Clin Ther. 2012;34(9):1954–63.
pubmed: 22939163
Blondell RD, Azadfard M, Wisniewski AM. Pharmacologic therapy for acute pain. Am Fam Physician. 2013;87(11):766–72.
pubmed: 23939498
Nafziger AN, Barkin RL. Opioid therapy in acute and chronic pain. J Clin Pharmacol. 2018;58(9):1111–22.
pubmed: 29985526
Bower WA, Johns M, Margolis HS, Williams IT, Bell BP. Population-based surveillance for acute liver failure. Am J Gastroenterol. 2007;102(11):2459–63.
pubmed: 17608778
The American Society of Anesthesiologists Task Force on Acute Pain Management. Practice guidelines for acute pain management in the perioperative setting. Anesthesiology. 2012;116(2):248–73.
Macrae WA. Chronic post-surgical pain: 10 years on. Br J Anaesth. 2008;101(1):77–86.
pubmed: 18434337
Substance Abuse and Mental Health Services Administration. Naltrexone [Internet]. Substance abuse and mental health services administration. 2023 [cited 2023 Jan 26]. Available from: https://www.samhsa.gov/medications-substance-use-disorders/medications-counseling-related-conditions/naltrexone .
Bell A. The neurobiology of acute pain. Vet J. 2018;237:55–62.
pubmed: 30089546
Sinatra R. Causes and consequences of inadequate management of acute pain. Pain Med. 2010;11(12):1859–71.
pubmed: 21040438
Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell. 2009;139(2):267–84.
pubmed: 19837031
pmcid: 2852643
Meyer RA. Peripheral mechanisms of cutaneous nociception. Wall Melzacks Textb Pain. 2006.
Hutchison RW. Challenges in acute post-operative pain management. Am J Health Syst Pharm. 2007;64(6_Supplement_4):S2–5.
pubmed: 17353557
Small C, Laycock H. Acute postoperative pain management. J Br Surg. 2020;107(2):e70-80.
Carr DB, Goudas LC. Acute pain. The Lancet. 1999;353(9169):2051–8.
Wu CL, Raja SN. Treatment of acute postoperative pain. The lancet. 2011;377(9784):2215–25.
Aboujaoude E, Salame WO. Naltrexone: a pan-addiction treatment? CNS Drugs. 2016;30(8):719–33.
pubmed: 27401883
Food and Drug Administration. Vivitrol highlights of prescribing information [Internet]. Food and Drug Administration; 2010. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021897s015lbl.pdf .
Potenza MN. Should addictive disorders include non-substance-related conditions? Addiction. 2006;101:142–51.
pubmed: 16930171
Petry NM. Should the scope of addictive behaviors be broadened to include pathological gambling? Addiction. 2006;101:152–60.
pubmed: 16930172
Verdejo-García A, Lawrence AJ, Clark L. Impulsivity as a vulnerability marker for substance-use disorders: review of findings from high-risk research, problem gamblers and genetic association studies. Neurosci Biobehav Rev. 2008;32(4):777–810.
pubmed: 18295884
Olmstead MC, Ouagazzal AM, Kieffer BL. Mu and delta opioid receptors oppositely regulate motor impulsivity in the signaled nose poke task. Hashimoto K, editor. PLoS ONE. 2009;4(2):e4410.
pubmed: 19198656
pmcid: 2635474
Kim SW, Grant JE, Adson DE, Remmel RP. A preliminary report on possible naltrexone and nonsteroidal analgesic interactions. J Clin Psychopharmacol. 2001;21(6):632–4.
pubmed: 11763022
Yoburn BC, Luke MC, Pasternak GW, Inturrisi CE. Upregulation of opioid receptor subtypes correlates with potency changes of morphine and dadle. Life Sci. 1988;43(16):1319–24.
pubmed: 2845219
Vickers JA. Naltrexone and problems in pain management. BMJ. 2006;332.
Br JP. Naltrexone: a review of its pharmacodynamics and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs. 1988;35:192–213.
Kranzler HR, Soyka M. Diagnosis and pharmacotherapy of alcohol use disorder: a review. JAMA. 2018;320(8):815–24.
pubmed: 30167705
pmcid: 7391072
Singh D, Saadabadi A. Naltrexone. 2018.
Schmidhammer H. Opioid receptor antagonists. Prog Med Chem. 1998;35:83–132.
pubmed: 10795400
Lobmaier PP, Kunøe N, Gossop M, Waal H. Naltrexone depot formulations for opioid and alcohol dependence: a systematic review. CNS Neurosci Ther. 2011;17(6):629–36.
pubmed: 21554565
Kirchmayer U, Davoli M, Verster A. Naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2003;(2).
Avery J. Naltrexone and alcohol use. Am J Psychiatry. 2022;179(12):886–7.
pubmed: 36453035
Mason BJ, Heyser CJ. Alcohol use disorder: the role of medication in recovery. Alcohol Res Curr Rev. 2021;41(1).
Santos GM, Ikeda J, Coffin P, Walker J, Matheson T, Ali A, et al. Targeted oral naltrexone for mild to moderate alcohol use disorder among sexual and gender minority men: a randomized trial. Am J Psychiatry. 2022;179(12):915–26.
pubmed: 36285404
pmcid: 10072332
Ciraulo AROS. DAcombine Study Research Group Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2003;2006(29517):2017.
Pettinati HM, Volpicelli JR, Pierce JD Jr, O’brien CP. Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis. 2000;19(1):71–83.
pubmed: 10772604
Anton RF. Naltrexone for the management of alcohol dependence. N Engl J Med. 2008;359(7):715–21.
pubmed: 18703474
pmcid: 2565602
Kim PS, Fishman MA. Low-dose naltrexone for chronic pain: update and systemic review. Curr Pain Headache Rep. 2020;24:1–8.
Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn’s disease, and other chronic pain disorders. Pharmacother J Hum Pharmacol Drug Ther. 2018;38(3):382–9.
Jagla C, Martus P, Stein C. Peripheral opioid receptor blockade increases postoperative morphine demands—a randomized, double-blind, placebo-controlled trial. Pain. 2014;155(10):2056–62.
pubmed: 25046272
Brown DR, Goldberg LI. The use of quaternary narcotic antagonists in opiate research. Neuropharmacology. 1985;24(3):181–91.
pubmed: 2986035
Russell J, Bass P, Goldberg LI, Schuster CR, Merz H. Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. Eur J Pharmacol. 1982;78(3):255–61.
pubmed: 7200037
Wiftels B, Glosten B, Faure EAM, Moawad AH, Ismail M, Hibbard J, et al. Opioid antagonist adjuncts to epidural morphine for postcesarean analgesia: maternal outcomes. Anesth Analg. 1993.
Lesscher HMB, Bailey A, Burbach JPH, Van Ree JM, Kitchen I, Gerrits MAFM. Receptor-selective changes in μ-, δ- and κ-opioid receptors after chronic naltrexone treatment in mice: Opioid receptor regulation by chronic naltrexone. Eur J Neurosci. 2003;17(5):1006–12.
pubmed: 12653976
Dı́az A, Pazos A, Flórez J, Ayesta FJ, Santana V, Hurlé MA. Regulation of μ-opioid receptors, G-protein-coupled receptor kinases and β-arrestin 2 in the rat brain after chronic opioid receptor antagonism. Neuroscience. 2002;112(2):345–53.
Tempel A, Gardner EL, Zukin RS. Neurochemical and functional correlates of naltrexone-induced opiate receptor up-regulation. J Pharmacol Exp Ther. 1985;232(2):439–44.
pubmed: 2982011
Curatolo C, Trinh M. Challenges in the perioperative management of the patient receiving extended-release naltrexone. Case Rep. 2014;3(11):142–4.
Dean RL, Todtenkopf MS, Deaver DR, Arastu MF, Dong N, Reitano K, et al. Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone. Pharmacol Biochem Behav. 2008;89(4):515–22.
pubmed: 18342360
Kapila A, Glass PSA, Jacobs JR, Muir KT, Hermann DJ, Shiraishi M, et al. Measured context-sensitive half-times of remifentanil and alfentanil. Anesthesiology. 1995;83(5):968–75.
pubmed: 7486182
Devlin JW, Skrobik Y, Gélinas C, Needham DM, Slooter AJC, Pandharipande PP, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46(9):e825–73.
pubmed: 30113379
Wampole CR, Smith KE. Beyond opioids for pain management in adult critically ill patients. J Pharm Pract. 2019;32(3):256–70.
pubmed: 30845871
Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. Anesth Analg. 1998;87(5):1186.
pubmed: 9806706
Garthwaite J. Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci. 1991;14(2):60–7.
pubmed: 1708538
Hustveit O, Maurset A, Oye I. Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol. 1995;77(6):355–9.
pubmed: 8835358
Smith DJ, Bouchal RL, deSanctis CA, Monroe PJ, Amedro JB, Perrotti JM, et al. Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro. Neuropharmacology. 1987;26(9):1253–60.
pubmed: 2823161
Wagner LE, Gingrich KJ, Kulli JC, Yang J. Ketamine blockade of voltage-gated sodium channels: evidence for a shared receptor site with local anesthetics. Anesthesiology. 2001;95(6):1406–13.
pubmed: 11748399
Mion G, Villevieille T. Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther. 2013;19(6):370–80.
pubmed: 23575437
pmcid: 6493357
Schwenk ES, Viscusi ER, Buvanendran A, Hurley RW, Wasan AD, Narouze S, et al. Consensus guidelines on the use of intravenous ketamine infusions for acute pain management from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018;43(5):456–66.
pubmed: 29870457
pmcid: 6023582
Brinck EC, Tiippana E, Heesen M, Bell RF, Straube S, Moore RA, et al. Perioperative intravenous ketamine for acute postoperative pain in adults. Cochrane Database Syst Rev [Internet]. 2018 [cited 2023 Jan 14];(12). Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012033.pub4/full .
Gharaei B, Jafari A, Aghamohammadi H, Kamranmanesh M, Poorzamani M, Elyassi H, et al. Opioid-sparing effect of preemptive bolus low-dose ketamine for moderate sedation in opioid abusers undergoing extracorporeal shock wave lithotripsy: a randomized clinical trial. Anesth Analg. 2013;116(1):75–80.
pubmed: 23223117
Do SH. Magnesium: a versatile drug for anesthesiologists. Korean J Anesthesiol. 2013;65(1):4–8.
pubmed: 23904932
pmcid: 3726845
Toleska M, Dimitrovski A, Shosholcheva M, Kartalov A, Kuzmanovska B, Dimitrovska NT. Pain and multimodal analgesia in laparoscopic cholecystectomy. Pril Makedon Akad Na Nauk Umet Oddelenie Za Med Nauki. 2022;43(2):41–9.
Liam BL, Yim CF, Chong JL. Dose response study of lidocaine 1% for spinal anaesthesia for lower limb and perineal surgery. Can J Anaesth J Can Anesth. 1998;45(7):645–50.
Schneider M, Ettlin T, Kaufmann M, Schumacher P, Urwyler A, Hampl K, et al. Transient neurologic toxicity after hyperbaric subarachnoid anesthesia with 5% lidocaine. Anesth Analg. 1993;76(5):1154–7.
pubmed: 8141862
Hampl KF, Heinzmann-Wiedmer S, Luginbuehl I, Harms C, Seeberger M, Schneider MC, et al. Transient neurologic symptoms after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine. Anesthesiology. 1998;88(3):629–33.
pubmed: 9523805
Chernoff DM. Kinetic analysis of phasic inhibition of neuronal sodium currents by lidocaine and bupivacaine. Biophys J. 1990;58(1):53–68.
pubmed: 2166601
pmcid: 1280940
Sahmeddini MA, Khosravi MB, Farbood A. Comparison of perioperative systemic lidocaine or systemic ketamine in acute pain management of patients with opioid use disorder after orthopedic surgery. J Addict Med. 2019;13(3):220–6.
pubmed: 30499871
Malik O, Kaye AD, Kaye A, Belani K, Urman RD. Emerging roles of liposomal bupivacaine in anesthesia practice. J Anaesthesiol Clin Pharmacol. 2017;33(2):151–6.
pubmed: 28781438
pmcid: 5520585
Tran AT, Rizk E, Haas EM, Naufal G, Zhong L, Swan JT. Real-world data on liposomal bupivacaine and inpatient hospital costs after colorectal surgery. J Surg Res. 2022;272:175–83.
pubmed: 34999518
Mont MA, Beaver WB, Dysart SH, Barrington JW, Del Gaizo DJ. Local infiltration analgesia with liposomal bupivacaine improves pain scores and reduces opioid use after total knee arthroplasty: results of a randomized controlled trial. J Arthroplasty. 2018;33(1):90–6.
pubmed: 28802777
Iyengar S, Webster AA, Hemrick-Luecke SK, Xu JY, Simmons RMA. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther. 2004;311(2):576–84.
pubmed: 15254142
YaDeau JT, Mayman DJ, Jules-Elysee KM, Lin Y, Padgett DE, DeMeo DA, et al. Effect of duloxetine on opioid use and pain after total knee arthroplasty: a triple-blinded randomized controlled trial. J Arthroplasty. 2022;37(6S):S147–54.
pubmed: 35346549
Zorrilla-Vaca A, Stone A, Caballero-Lozada AF, Paredes S, Grant MC. Perioperative duloxetine for acute postoperative analgesia: a meta-analysis of randomized trials. Reg Anesth Pain Med. 2019;rapm-2019-100687.
Cheifetz O, Lucy SD, Overend TJ, Crowe J. The effect of abdominal support on functional outcomes in patients following major abdominal surgery: a randomized controlled trial. Physiother Can Physiother Can. 2010;62(3):242–53.
pubmed: 21629603
Hoskins C, Dempsey A, Brou L. A mixed-methods study of the effect of abdominal binders on opioid use and postoperative pain after cesarean birth. Nurs Womens Health. 2022;26(1):30–7.
pubmed: 35032465
Armaghani SJ, Lee DS, Bible JE, Archer KR, Shau DN, Kay H, et al. Preoperative opioid use and its association with perioperative opioid demand and postoperative opioid independence in patients undergoing spine surgery. Spine. 2014;39(25):E1524-1530.
pubmed: 25417827
Uhrbrand P, Rasmussen MM, Haroutounian S, Nikolajsen L. Shared decision-making approach to taper postoperative opioids in spine surgery patients with preoperative opioid use: a randomized controlled trial. Pain. 2022;163(5):e634–41.
pubmed: 34433772